Since the PI3K pathway is a driver of uncontrolled growth and spread of a variety of cancers, there are currently academic and clinical efforts in place to develop PI3K, AKT, and mTOR inhibitors as cancer therapeutics (Yang et al., 2019; Castel et al., 2021). This evidence concerns the gene AKT1 and cancer.